Context Therapeutics Inc. (CNTX)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-06. ClinicalTrials.gov
Dilution Risk
MEDIUM DILUTION RISKDilution score: 40/100 (MEDIUM), 19.4 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 16.13% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Context drops bispecific T-cell engager on cost-cutting initiative
- Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Context Therapeutics Added to Russell 2000® and Russell 3000® Indexes
- Small Biotech Context Therapeutics Reports 29% Response Rate In Ovarian Cancer Study
- Context Therapeutics Announces Positive Interim Efficacy and Safety Results from Ongoing Phase 1 Clinical Trial for CTIM-76
- Context Therapeutics to Present at the Jefferies Global Healthcare Conference
- Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202
- Context Therapeutics Reports First Quarter 2026 Operating and Financial Results
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Context Therapeutics Inc..
Full CNTX Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.